|
AbbVie’s Born — What Now?
Motley Fool Multiple sclerosis treatment daclizumab, a partnership project with Biogen Idec (NASDAQ: BIIB ) , should report data sometime next year. Brian Orelli discussed the mid-stage trial results containing promising efficacy better than Teva’s (NYSE: TEVA ) … |
AbbVie targets 2015 growth with focus on new specialty drugsChicago Daily HeraldAbbVie also is developing daclizumab, a treatment for multiple sclerosis in the late stage of clinical trials that may reach the market by late 2015 or early 2016. Finally,…
Abatacept effectively, safely treated RA patients who failed anti-TNF …HealioAbatacept was safe and effective therapy for patients with severe rheumatoid arthritis who had failed to respond to anti-tumor necrosis factor therapy and rituximab in a rec…
Drug combination acts against aggressive chronic lymphocytic leukemiaOncology Nurse AdvisorThis phase II study enrolled 40 patients with high-risk CLL, who received daily oral doses of 420 mg ibrutinib throughout treatment, weekly infusions of 375 mg/m…
AbbVie targets 2015 growth with focus on new specialty drugsWorcester TelegramAbbVie also is developing daclizumab, a treatment for multiple sclerosis in the late stage of clinical trials that may reach the market by late 2015 or early 2016. Finally, t…
AbbVie Plans Specialty Drug Focus in Sales Growth EffortBloombergAbbVie also is developing daclizumab, a treatment for multiple sclerosis in the late stage of clinical trials that may reach the market by late 2015 or early 2016. Finally, the company ha…
Rituxan Add-On Curbs RA Joint DamageMedPage TodayAdding the B-cell depleting agent rituximab (Rituxan) to methotrexate slowed joint damage progression in patients with rheumatoid arthritis (RA) regardless of the level of disease activity, Austrian rese…
Ibrutinib appears safe, effective against chronic lymphocytic leukemiaOncology Nurse AdvisorAs explained in an ASH statement, primary treatment for CLL includes a combined chemotherapy-based regimen with fludarabine and cyclophosphamide, along with the…
Researchers identify rituximab-insensitive cells in patients with refractory …Science CodexPrimary immune thrombocytopenia purpura (ITP) is a bleeding disorder in which the immune system generates antibodies that destroy platelets, the cells that cau…
|
AbbVie Wants To Be Hunter, Not Hunted Post-Abbott Split
Forbes There are 10 drugs in the final so-called Phase III stage of drug development including a potentially promising next-generation hepatitis C drug; the intestinal gel Duopa for the treatment of advanced Parkinson’s disease; daclizumab for multiple … Which Abbott Is the One to Own Post-Split?Investorplace.com |